{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T08:41:22Z","timestamp":1778575282394,"version":"3.51.4"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T00:00:00Z","timestamp":1706054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T00:00:00Z","timestamp":1706054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100006752","name":"Universidade do Porto","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006752","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s40257-024-00845-4","type":"journal-article","created":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T14:36:44Z","timestamp":1706107004000},"page":"333-342","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Treatment of Psoriasis Patients with Latent Tuberculosis Using IL-17 and IL-23 Inhibitors: A Retrospective, Multinational, Multicentre Study"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0404-0870","authenticated-orcid":false,"given":"Tiago","family":"Torres","sequence":"first","affiliation":[]},{"given":"Andrea","family":"Chiricozzi","sequence":"additional","affiliation":[]},{"given":"Luis","family":"Puig","sequence":"additional","affiliation":[]},{"given":"Ana Maria","family":"L\u00e9","sequence":"additional","affiliation":[]},{"given":"Angelo Valerio","family":"Marzano","sequence":"additional","affiliation":[]},{"given":"Paolo","family":"Dapavo","sequence":"additional","affiliation":[]},{"given":"Esteban","family":"Dauden","sequence":"additional","affiliation":[]},{"given":"J\u03ccse-Manuel","family":"Carrascosa","sequence":"additional","affiliation":[]},{"given":"Elizabeth","family":"Lazaridou","sequence":"additional","affiliation":[]},{"given":"Gleison","family":"Duarte","sequence":"additional","affiliation":[]},{"given":"Andr\u00e9 V. E.","family":"Carvalho","sequence":"additional","affiliation":[]},{"given":"Ricardo","family":"Romiti","sequence":"additional","affiliation":[]},{"given":"Natalia","family":"Rompoti","sequence":"additional","affiliation":[]},{"given":"Laetitia","family":"Teixeira","sequence":"additional","affiliation":[]},{"given":"Miguel","family":"Abreu","sequence":"additional","affiliation":[]},{"given":"Elena","family":"Ippoliti","sequence":"additional","affiliation":[]},{"given":"Carlo Alberto","family":"Maronese","sequence":"additional","affiliation":[]},{"given":"Mar","family":"Llamas-Velasco","sequence":"additional","affiliation":[]},{"given":"Eva","family":"Vilarrasa","sequence":"additional","affiliation":[]},{"given":"Elena","family":"del Alc\u00e1zar","sequence":"additional","affiliation":[]},{"given":"Athina-Ioanna","family":"Daponte","sequence":"additional","affiliation":[]},{"given":"Marina","family":"Papoutsaki","sequence":"additional","affiliation":[]},{"given":"Andrea","family":"Carugno","sequence":"additional","affiliation":[]},{"given":"Francesco","family":"Bellinato","sequence":"additional","affiliation":[]},{"given":"Paolo","family":"Gisondi","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2024,1,24]]},"reference":[{"issue":"11","key":"845_CR1","doi-asserted-by":"publisher","first-page":"263","DOI":"10.15585\/mmwr.mm6811a3","volume":"68","author":"A MacNeil","year":"2019","unstructured":"MacNeil A, Glaziou P, Sismanidis C, Maloney S, Floyd K. Global epidemiology of tuberculosis and progress toward achieving global targets\u20142017. MMWR Morb Mortal Wkly Rep. 2019;68(11):263\u20136.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"2","key":"845_CR2","volume":"5","author":"J-W Ai","year":"2016","unstructured":"Ai J-W, Ruan Q-L, Liu Q-H, Zhang W-H. Updates on the risk factors for latent tuberculosis reactivation and their managements. Emerg Microbes Infect. 2016;5(2): e10.","journal-title":"Emerg Microbes Infect."},{"issue":"19","key":"845_CR3","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","volume":"323","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945\u201360.","journal-title":"JAMA"},{"issue":"5","key":"845_CR4","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1080\/09546634.2020.1746734","volume":"31","author":"S Gerdes","year":"2020","unstructured":"Gerdes S, Korber A, Biermann M, Karnthaler C, Reinhardt M. Absolute and relative psoriasis area and severity index (PASI) treatment goals and their association with health-related quality of life. J Dermatol Treat. 2020;31(5):470\u20135.","journal-title":"J Dermatol Treat"},{"issue":"6","key":"845_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms20061475","volume":"20","author":"A Rendon","year":"2019","unstructured":"Rendon A, Sch\u00e4kel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019;20(6):1\u201328.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"845_CR6","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.4049\/jimmunol.1800013","volume":"201","author":"JE Hawkes","year":"2018","unstructured":"Hawkes JE, Yan BY, Chan TC, Krueger JG. Discovery of the IL-23\/IL-17 signaling pathway and the treatment of psoriasis. J Immunol. 2018;201(6):1605\u201313.","journal-title":"J Immunol"},{"issue":"3","key":"845_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-012567","volume":"7","author":"Z Zhang","year":"2017","unstructured":"Zhang Z, Fan W, Yang G, et al. Risk of tuberculosis in patients treated with TNF-\u03b1 antagonists: a systematic review and meta-analysis of randomised controlled trials. BMJ Open. 2017;7(3): e012567.","journal-title":"BMJ Open"},{"issue":"10","key":"845_CR8","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1093\/rheumatology\/keu172","volume":"53","author":"A Souto","year":"2014","unstructured":"Souto A, Maneiro JR, Salgado E, Carmona L, Gomez-Reino JJ. Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies. Rheumatology (Oxford). 2014;53(10):1872\u201385.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"845_CR9","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.autrev.2015.01.011","volume":"14","author":"F Cantini","year":"2015","unstructured":"Cantini F, Nannini C, Niccoli L, et al. Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice. Autoimmun Rev. 2015;14(6):503\u20139.","journal-title":"Autoimmun Rev"},{"issue":"5","key":"845_CR10","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1172\/JCI39143","volume":"119","author":"EA Miller","year":"2009","unstructured":"Miller EA, Ernst JD. Anti-TNF immunotherapy and tuberculosis reactivation: another mechanism revealed. J Clin Invest. 2009;119(5):1079\u201382.","journal-title":"J Clin Invest"},{"issue":"2","key":"845_CR11","doi-asserted-by":"publisher","first-page":"788","DOI":"10.4049\/jimmunol.175.2.788","volume":"175","author":"SA Khader","year":"2005","unstructured":"Khader SA, Pearl JE, Sakamoto K, et al. IL-23 compensates for the absence of IL-12p70 and is essential for the IL-17 response during tuberculosis but is dispensable for protection and antigen-specific IFN-gamma responses if IL-12p70 is available. J Immunol. 2005;175(2):788\u201395.","journal-title":"J Immunol"},{"issue":"11","key":"845_CR12","doi-asserted-by":"publisher","first-page":"6092","DOI":"10.1128\/IAI.00621-06","volume":"74","author":"AA Chackerian","year":"2006","unstructured":"Chackerian AA, Chen S-J, Brodie SJ, et al. Neutralization or absence of the interleukin-23 pathway does not compromise immunity to mycobacterial infection. Infect Immun. 2006;74(11):6092\u20139.","journal-title":"Infect Immun"},{"issue":"8","key":"845_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/cti.2017.34","volume":"6","author":"M Kamm\u00fcller","year":"2017","unstructured":"Kamm\u00fcller M, Tsai T-F, Griffiths CE, et al. Inhibition of IL-17A by secukinumab shows no evidence of increased Mycobacterium tuberculosis infections. Clin Transl Immunol. 2017;6(8): e152.","journal-title":"Clin Transl Immunol."},{"issue":"4","key":"845_CR14","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1111\/jdv.16866","volume":"35","author":"M Nogueira","year":"2021","unstructured":"Nogueira M, Warren RB, Torres T. Risk of tuberculosis reactivation with interleukin (IL)-17 and IL-23 inhibitors in psoriasis\u2014time for a paradigm change. J Eur Acad Dermatol Venereol. 2021;35(4):824\u201334.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"845_CR15","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/bjd.19039","volume":"183","author":"CH Smith","year":"2020","unstructured":"Smith CH, Yiu ZZN, Bale T, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update. Br J Dermatol. 2020;183(4):628\u201337.","journal-title":"Br J Dermatol"},{"issue":"1","key":"845_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6901a1","volume":"69","author":"TR Sterling","year":"2020","unstructured":"Sterling TR, Njie G, Zenner D, et al. Guidelines for the treatment of latent tuberculosis infection: recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR Recomm Rep. 2020;69(1):1\u201311.","journal-title":"MMWR Recomm Rep"},{"key":"845_CR17","unstructured":"World Health Organization. Guidelines on the management of latent tuberculosis infection [Internet]. (2015). Available from: http:\/\/www.who.int\/tb\/publications\/latent-tuberculosis-infection\/en\/."},{"issue":"10","key":"845_CR18","doi-asserted-by":"publisher","first-page":"e327","DOI":"10.1016\/S1473-3099(17)30248-7","volume":"17","author":"PA LoBue","year":"2017","unstructured":"LoBue PA, Mermin JH. Latent tuberculosis infection: the final frontier of tuberculosis elimination in the USA. Lancet Infect Dis. 2017;17(10):e327\u201333.","journal-title":"Lancet Infect Dis"},{"key":"845_CR19","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1146\/annurev.immunol.20.081501.125851","volume":"20","author":"J-L Casanova","year":"2002","unstructured":"Casanova J-L, Abel L. Genetic dissection of immunity to mycobacteria: the human model. Annu Rev Immunol. 2002;20:581\u2013620.","journal-title":"Annu Rev Immunol"},{"issue":"7","key":"845_CR20","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1038\/s41423-021-00694-9","volume":"18","author":"M Robert","year":"2021","unstructured":"Robert M, Miossec P. Reactivation of latent tuberculosis with TNF inhibitors: critical role of the beta 2 chain of the IL-12 receptor. Cell Mol Immunol. 2021;18(7):1644\u201351.","journal-title":"Cell Mol Immunol"},{"issue":"5","key":"845_CR21","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1111\/j.1365-2133.2012.11142.x","volume":"167","author":"T-F Tsai","year":"2012","unstructured":"Tsai T-F, Ho V, Song M, et al. The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection. Br J Dermatol. 2012;167(5):1145\u201352.","journal-title":"Br J Dermatol"},{"issue":"4","key":"845_CR22","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1684\/ejd.2014.2386","volume":"24","author":"E Errichetti","year":"2014","unstructured":"Errichetti E, Piccirillo A. Latent tuberculosis reactivation in a patient with erythrodermic psoriasis under treatment with ustekinumab and a low dose steroid, despite isoniazid chemoprophylaxis. Eur J Dermatol. 2014;24(4):508\u20139.","journal-title":"Eur J Dermatol"},{"issue":"2","key":"845_CR23","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1111\/j.1365-2133.2012.11162.x","volume":"168","author":"T-F Tsai","year":"2013","unstructured":"Tsai T-F, Chiu H-Y, Song M, Chan D. A case of latent tuberculosis reactivation in a patient treated with ustekinumab without concomitant isoniazid chemoprophylaxis in the PEARL trial. Br J Dermatol. 2013;168(2):444\u20136.","journal-title":"Br J Dermatol"},{"issue":"3","key":"845_CR24","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.jdcr.2017.02.001","volume":"3","author":"M Lynch","year":"2017","unstructured":"Lynch M, Roche L, Horgan M, Ahmad K, Hackett C, Ramsay B. Peritoneal tuberculosis in the setting of ustekinumab treatment for psoriasis. JAAD Case Rep. 2017;3(3):230\u20132.","journal-title":"JAAD Case Rep."},{"issue":"4","key":"845_CR25","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s40257-019-00432-y","volume":"20","author":"I Snast","year":"2019","unstructured":"Snast I, Bercovici E, Solomon-Cohen E, et al. Active tuberculosis in patients with psoriasis receiving biologic therapy: a systematic review. Am J Clin Dermatol. 2019;20(4):483\u201391.","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"845_CR26","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/path.5013","volume":"244","author":"S Singh","year":"2018","unstructured":"Singh S, Maniakis-Grivas G, Singh UK, et al. Interleukin-17 regulates matrix metalloproteinase activity in human pulmonary tuberculosis. J Pathol. 2018;244(3):311\u201322.","journal-title":"J Pathol"},{"issue":"7762","key":"845_CR27","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1038\/s41586-019-1276-2","volume":"570","author":"A Ardain","year":"2019","unstructured":"Ardain A, Domingo-Gonzalez R, Das S, et al. Group 3 innate lymphoid cells mediate early protective immunity against tuberculosis. Nature. 2019;570(7762):528\u201332.","journal-title":"Nature"},{"key":"845_CR28","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/854507","volume":"2015","author":"IV Lyadova","year":"2015","unstructured":"Lyadova IV, Panteleev AV. Th1 and Th17 cells in tuberculosis: protection, pathology, and biomarkers. Mediators Inflamm. 2015;2015: 854507.","journal-title":"Mediators Inflamm"},{"key":"845_CR29","doi-asserted-by":"publisher","first-page":"8909834","DOI":"10.1155\/2017\/8909834","volume":"2017","author":"F Cantini","year":"2017","unstructured":"Cantini F, Nannini C, Niccoli L, Petrone L, Ippolito G, Goletti D. Risk of tuberculosis reactivation in patients with rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis receiving non-anti-tnf-targeted biologics. Mediators Inflamm. 2017;2017:8909834.","journal-title":"Mediators Inflamm"},{"issue":"2","key":"845_CR30","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.4049\/jimmunol.176.2.1098","volume":"176","author":"MA Kleinschek","year":"2006","unstructured":"Kleinschek MA, Muller U, Brodie SJ, et al. IL-23 enhances the inflammatory cell response in Cryptococcus neoformans infection and induces a cytokine pattern distinct from IL-12. J Immunol. 2006;176(2):1098\u2013106.","journal-title":"J Immunol"},{"key":"845_CR31","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3389\/fimmu.2017.00294","volume":"8","author":"BC Mourik","year":"2017","unstructured":"Mourik BC, Lubberts E, de Steenwinkel JEM, Ottenhoff THM, Leenen PJM. Interactions between Type 1 interferons and the Th17 response in tuberculosis: lessons learned from autoimmune diseases. Front Immunol. 2017;8:294.","journal-title":"Front Immunol"},{"issue":"6","key":"845_CR32","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.cytogfr.2010.10.004","volume":"21","author":"E Torrado","year":"2010","unstructured":"Torrado E, Cooper AM. IL-17 and Th17 cells in tuberculosis. Cytokine Growth Factor Rev. 2010;21(6):455\u201362.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"4","key":"845_CR33","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1080\/14740338.2020.1736034","volume":"19","author":"Y-W Huang","year":"2020","unstructured":"Huang Y-W, Tsai T-F. A drug safety evaluation of risankizumab for psoriasis. Expert Opin Drug Saf. 2020;19(4):395\u2013402.","journal-title":"Expert Opin Drug Saf"},{"issue":"Suppl 1","key":"845_CR34","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1159\/000501989","volume":"11","author":"S Ribero","year":"2019","unstructured":"Ribero S, Licciardello M, Quaglino P, Dapavo P. Efficacy and safety of secukinumab in patients with plaque psoriasis and latent tuberculosis. Case Rep Dermatol. 2019;11(Suppl 1):23\u20138.","journal-title":"Case Rep Dermatol"},{"issue":"5","key":"845_CR35","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1080\/09546634.2022.2062280","volume":"33","author":"M Megna","year":"2022","unstructured":"Megna M, Patruno C, Bongiorno MR, et al. Lack of reactivation of tuberculosis in patients with psoriasis treated with secukinumab in a real-world setting of latent tuberculosis infection. J Dermatolog Treat. 2022;33(5):2629\u201333.","journal-title":"J Dermatolog Treat"},{"issue":"5","key":"845_CR36","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1016\/j.jaad.2020.06.012","volume":"83","author":"U Mrowietz","year":"2020","unstructured":"Mrowietz U, Riedl E, Winkler S, et al. No reactivation of tuberculosis in patients with latent tuberculosis infection receiving ixekizumab: a report from 16 clinical studies of patients with psoriasis or psoriatic arthritis. J Am Acad Dermatol. 2020;83(5):1436\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"845_CR37","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1111\/jdv.19406","volume":"38","author":"N Manzanares","year":"2024","unstructured":"Manzanares N, Vilarrasa E, L\u00f3pez A, et al. No tuberculosis reactivations in psoriasis patients initiating new generation biologics despite untreated latent tuberculosis infection: multicenter case series of 35 patients. J Eur Acad Dermatol Venereol. 2024;38(1):e26\u20138.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"845_CR38","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13075-019-1882-2","volume":"21","author":"A Deodhar","year":"2019","unstructured":"Deodhar A, Mease PJ, McInnes IB, et al. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. Arthritis Res Ther. 2019;21(1):111.","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"845_CR39","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s13555-020-00367-x","volume":"10","author":"C Leonardi","year":"2020","unstructured":"Leonardi C, Reich K, Foley P, et al. Efficacy and safety of ixekizumab through 5 years in moderate-to-severe psoriasis: long-term results from the UNCOVER-1 and UNCOVER-2 phase-3 randomized controlled trials. Dermatol Ther (Heidelb). 2020;10(3):431\u201347.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"3","key":"845_CR40","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1111\/bjd.16724","volume":"179","author":"A Blauvelt","year":"2018","unstructured":"Blauvelt A, Reich K, Papp KA, et al. Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials. Br J Dermatol. 2018;179(3):615\u201322.","journal-title":"Br J Dermatol"},{"issue":"3","key":"845_CR41","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1136\/ard.2009.118935","volume":"69","author":"WG Dixon","year":"2010","unstructured":"Dixon WG, Hyrich KL, Watson KD, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis. 2010;69(3):522\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"845_CR42","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1093\/rheumatology\/keh567","volume":"44","author":"J Keane","year":"2005","unstructured":"Keane J. TNF-blocking agents and tuberculosis: new drugs illuminate an old topic. Rheumatology (Oxford). 2005;44(6):714\u201320.","journal-title":"Rheumatology (Oxford)"},{"issue":"11\u201312","key":"845_CR43","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1080\/00365540410025339","volume":"36","author":"AA Cagatay","year":"2004","unstructured":"Cagatay AA, Caliskan Y, Aksoz S, et al. Extrapulmonary tuberculosis in immunocompetent adults. Scand J Infect Dis. 2004;36(11\u201312):799\u2013806.","journal-title":"Scand J Infect Dis"},{"key":"845_CR44","doi-asserted-by":"publisher","first-page":"145","DOI":"10.2147\/DHPS.S68837","volume":"6","author":"JT Denholm","year":"2014","unstructured":"Denholm JT, McBryde ES, Eisen DP, Penington JS, Chen C, Street AC. Adverse effects of isoniazid preventative therapy for latent tuberculosis infection: a prospective cohort study. Drug Healthc Patient Saf. 2014;6:145\u20139.","journal-title":"Drug Healthc Patient Saf."},{"issue":"6","key":"845_CR45","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1111\/bcp.12885","volume":"81","author":"I Metushi","year":"2016","unstructured":"Metushi I, Uetrecht J, Phillips E. Mechanism of isoniazid-induced hepatotoxicity: then and now. Br J Clin Pharmacol. 2016;81(6):1030\u20136.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"845_CR46","doi-asserted-by":"publisher","first-page":"591","DOI":"10.2169\/internalmedicine.54.3669","volume":"54","author":"S Miyazawa","year":"2015","unstructured":"Miyazawa S, Matsuoka S, Hamana S, et al. Isoniazid-induced acute liver failure during preventive therapy for latent tuberculosis infection. Intern Med. 2015;54(6):591\u20135.","journal-title":"Intern Med"},{"key":"845_CR47","doi-asserted-by":"crossref","unstructured":"Li AA, Dibba P, Cholankeril G, Kim D, Ahmed A. Case report of isoniazid-related acute liver failure requiring liver transplantation. Diseases. 2018;6(2):40.","DOI":"10.3390\/diseases6020040"},{"issue":"8","key":"845_CR48","first-page":"224","volume":"59","author":"Centers for Disease Control and Prevention (CDC)","year":"2010","unstructured":"Centers for Disease Control and Prevention (CDC). Severe isoniazid-associated liver injuries among persons being treated for latent tuberculosis infection\u2014United States, 2004\u20132008. MMWR Morb Mortal Wkly Rep. 2010;59(8):224\u20139.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"845_CR49","first-page":"3617408","volume":"2016","author":"WK Kabbara","year":"2016","unstructured":"Kabbara WK, Sarkis AT, Saroufim PG. Acute and fatal isoniazid-induced hepatotoxicity: a case report and review of the literature. Case Rep Infect Dis. 2016;2016:3617408.","journal-title":"Case Rep Infect Dis."},{"issue":"6","key":"845_CR50","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1017\/S0950268811001476","volume":"140","author":"SH Lee","year":"2012","unstructured":"Lee SH, Yim J-J, Kim HJ, et al. Adverse events and development of tuberculosis after 4 months of rifampicin prophylaxis in a tuberculosis outbreak. Epidemiol Infect. 2012;140(6):1028\u201335.","journal-title":"Epidemiol Infect"},{"issue":"2","key":"845_CR51","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/j.1440-1746.2007.05207.x","volume":"23","author":"A Tostmann","year":"2008","unstructured":"Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WCM, van der Ven AJAM, Dekhuijzen R. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol. 2008;23(2):192\u2013202.","journal-title":"J Gastroenterol Hepatol"},{"issue":"11","key":"845_CR52","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0027610","volume":"6","author":"K Chung-Delgado","year":"2011","unstructured":"Chung-Delgado K, Revilla-Montag A, Guillen-Bravo S, et al. Factors associated with anti-tuberculosis medication adverse effects: a case\u2013control study in Lima, Peru. PLoS ONE. 2011;6(11): e27610.","journal-title":"PLoS ONE"},{"issue":"9","key":"845_CR53","doi-asserted-by":"publisher","first-page":"819","DOI":"10.2165\/00003088-200342090-00003","volume":"42","author":"M Niemi","year":"2003","unstructured":"Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivist\u00f6 KT. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet. 2003;42(9):819\u201350.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"845_CR54","doi-asserted-by":"publisher","first-page":"2241585","DOI":"10.1080\/09546634.2023.2241585","volume":"34","author":"L Ibba","year":"2023","unstructured":"Ibba L, Gargiulo L, Vignoli CA, et al. Safety of anti-IL-23 drugs in patients with moderate-to-severe plaque psoriasis and previous tuberculosis infection: a monocentric retrospective study. J Dermatol Treat. 2023;34(1):2241585.","journal-title":"J Dermatol Treat"},{"issue":"6","key":"845_CR55","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1684\/ejd.2020.3909","volume":"30","author":"\u00c1 Machado","year":"2020","unstructured":"Machado \u00c1, Abreu M, Torres T. Safety of secukinumab in psoriasis patients with latent tuberculosis infection. Eur J Dermatol. 2020;30(6):740\u20131.","journal-title":"Eur J Dermatol"},{"issue":"6","key":"845_CR56","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14512","volume":"33","author":"D Shu","year":"2020","unstructured":"Shu D, Zhang Z, Zhou EY, Ma X, Zhao Y. Is chemoprophylaxis necessary for all latent tuberculosis infection patients receiving IL-17 inhibitors? A cohort study. Dermatol Ther. 2020;33(6): e14512.","journal-title":"Dermatol Ther"},{"issue":"1","key":"845_CR57","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.5302","volume":"10","author":"C Fiorella","year":"2022","unstructured":"Fiorella C. Treatment with secukinumab for plaque psoriasis in patients with infectious comorbidities and latent tuberculosis: a multi-case report analysis. Clin Case Rep. 2022;10(1): e05302.","journal-title":"Clin Case Rep."}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-024-00845-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-024-00845-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-024-00845-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,18]],"date-time":"2024-02-18T23:08:49Z","timestamp":1708297729000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-024-00845-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,24]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["845"],"URL":"https:\/\/doi.org\/10.1007\/s40257-024-00845-4","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,24]]},"assertion":[{"value":"14 January 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No sources of funding were used to conduct this study or prepare this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Tiago Torres declares the following conflicts of interest: AbbVie, Almirall, Amgen, Arena Pharmaceuticals, Biocad, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Fresenius Kabi, Janssen, LEO Pharma, Eli Lilly, MSD, Mylan, Novartis, Pfizer, Samsung-Bioepis, Sanofi-Genzyme, Sandoz and UCB. Andrea Chiricozzi has served as advisory board member and consultant and has received fees and speaker\u2019s honoraria or has participated in clinical trials for AbbVie, Almirall, Bristol Myers Squibb, Leo Pharma, Lilly, Janssen, Novartis, Pfizer and Sanofi Genzyme. Lu\u00eds Puig has received consultancy and\/or speaker\u2019s honoraria from and\/or participated in clinical trials sponsored from AbbVie, Almirall, Amgen, Baxalta, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Fresenius-Kabi, Janssen, JS BIOCAD, LEO Pharma, Lilly, Mylan, Novartis, Pfizer, Regeneron, Roche, Sandoz, Samsung-Bioepis, Sanofi and UCB. Ana Maria L\u00e9 has no conflicts of interest. Angelo Valerio Marzano reports consultancy\/advisory board disease-relevant honoraria from AbbVie, Boehringer Ingelheim, Novartis, Pfizer, Sanofi and UCB. Paolo Dapavo has no conflicts of interest. Esteban Dauden has the following conflicts of interest: advisory board member, consultant, grants, research support, participation in clinical trials, honorarium for speaking, and research support, in connection with the following pharmaceutical companies: Abbvie\/Abbott, Almirall, Amgen-Celgene, Janssen-Cilag, Leo-Pharma, Novartis, Pfizer, MSD-Schering-Plough, Lilly, UCB, Brystol-Myers and Boehringer Ingelheim. Jos\u00e9-Manuel Carrascosa acted as a consultant and\/or speaker for and\/or participated in clinical trials sponsored by Janssen Pharmaceuticals Inc., Eli-Lilly, AbbVie, Novartis, Amgen, Leo-Pharma, UCB, Boehringer Ingelheim, Almirall, Sandoz and Bristol\u00a0Myers\u00a0Squibb. Elizabeth Lazaridou has the following conflicts of interest: speaker's honoraria from and participation in clinical studies and advisory boards with Abbvie, Leo, Novartis, Pfizer, UCB, Sanofi, Janssen, Lilly-Galderma, Pierre Fabre, L'Oreala and Galenica. Gleison Duarte is\/has served as a scientific consultant, speaker or clinical trial investigator for Abbvie, Bayer, Janssen, Leo\u2010Pharma, Galderma, Sanofi, Boehringer, Novartis, Pfizer and UCB. Andr\u00e9 V. E. de Carvalho: Dr Carvalho acted as a consultant and\/or speaker for and\/or participated in clinical trials sponsored by companies that manufacture drugs used for the treatment of psoriasis, including Janssen Pharmaceuticals Inc., Eli-Lilly, AbbVie, Novartis, Amgen, Leo-Pharma, UCB and Boehringer Ingelheim. Ricardo Romiti has received consulting fees from AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galderma, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi, and UCB Pharma; his institution has received research grants from AbbVie; and he has served as a paid speaker for AbbVie, Boehringer Ingelheim, Eli Lilly, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi and UCB\u00a0Pharma. Natalia Rompoti has received honoraria for lectures from Janssen, AbbVie, Genesis Pharma, Leo, Lilly Pharmaserve, Novartis and UCB, and support for scientific congress attendance from AbbVie, Janssen, Leo, Lilly Pharmaserve, Novartis and UCB. Laetitia Teixeira has no conflicts of interest to declare. Miguel Abreu has no conflicts of interest to declare. Elena Ippoliti has no conflicts of interest to declare. Carlo Alberto Maronese has no conflicts of interest to declare. Mar Llamas-Velasco has the following conflicts of interest: advisory board member, consultant, grants, research support, participation in clinical trials, honorarium for speaking, research support, in connection with the following pharmaceutical companies: Abbvie, Almirall, Amgen, Biogen, Celgene, Janssen-Cilag, Leo Pharma, Lilly, MSD, Novartis, Pfizer, UCB, Kyowa Kirin, Brystol-Myers and Boehringer Ingelheim. Eva Vilarrasa has received honoraria for acting as a consultant and\/or speaker for AbbVie, Almirall, Boehringer, Celgene, Janssen, Leo Pharma, Eli Lilly, MSD, Novartis, Pfizer and UCB. Elena del Alc\u00e1zar has participated as an Secondary investigator and\/or invited speaker for AbbVie, Janssen, Novartis, Lilly, Leo Pharma, Almirall, Amgen, UCB and Sanofi. Athina\u2011Ioanna Daponte has no conflicts to declare. Marina Papoutsaki has received honoraria for advisory boards and lectures from Janssen, Leo Pharma, MSD, Genesis Pharma, Pfizer, Novartis, AbbVie and UCB, and support as an investigator in clinical studies from AbbVie, Novartis, Leo Pharma and Janssen. Andrea Carugno has no conflicts of interest. Francesco Bellinato has no conflicts of interest. Paolo Gisondi has received honoraria for acting as a consultant and\/or speaker for AbbVie, Almirall, Amgen, Biogen, Bristol Myers Squibb, Celgene, Janssen, LEO Pharma, Eli Lilly, MSD, Novartis, Pierre Fabre, Sanofi and UCB.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The present study was conducted in accordance with the Declaration of Helsinki (initially published in 1964) on Ethical Principles for Medical Research Involving Human Subjects. Ethical approval was waived in view of the retrospective nature of the study, and all the procedures being performed were part of the routine care.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data are available within the article or its supplementary materials.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"TT and PG contributed to the study conception, design and statistical analyses; TT, AML, FB and PG contributed to manuscript writing. All authors contributed to data collection and interpretation of the data, provided critical feedback on the manuscript, approved the final manuscript for submission, and were accountable for the accuracy and integrity of the article.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}